Predicting improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray
Feldman, S.R.; Winkelman, W.; Baum, E.; Preston, N.
Journal of Drugs in Dermatology Jdd 12(12): 1456-1460
2013
ISSN/ISBN: 1545-9616 PMID: 24301248 Document Number: 14179
One of the hurdles to effectively managing plaque psoriasis is lack of adherence to prescribed treatments. Up to 40% of subjects report they do not adhere to their medication for a variety of reasons. Earlier response to treatment may be a motivator for subjects to better adhere to treatment. Clobetasol propionate 0.05% spray (CPS) is a highly potent topical corticosteroid indicated for the treatment of moderate to severe plaque psoriasis that has efficacy as early as 1 week after initiating therapy. Using data from the 2 CPS pivotal trials, a post hoc analysis was performed to determine the relationship between week 1 improvements and week 4 treatment success (defined as a score of 0 ). Improvements in week 1 ODS and pruritus were predictive of week 4 treatment success. Subjects who had ODS or pruritus scores of moderate or better at week 1 tended to be treatment successes at week 4 whereas no relationship between week 1 scores and week 4 treatment success was observed for those treated with vehicle spray. The results of this post hoc analysis indicate that early improvement correlates to treatment success.
Document emailed within 1 workday
